{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:09:36Z","timestamp":1755216576793,"version":"3.43.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Juvenile dermatomyositis (JDM) is the most popular subtype of juvenile idiopathic inflammatory myopathies clinically characterised by skin manifestations and myositis. Some patients with JDM present predominantly with skin symptoms without significant muscle weakness. Furthermore, some patients exhibit residual skin disease even after showing improvement of muscle symptoms with systemic glucocorticoids (GCs) and immunosuppressants. Topical GCs and\/or tacrolimus are recommended for the patients with skin predominant JDM. Furthermore, systemic use of GCs and methotrexate (MTX) are indicated in refractory cases. However, some patients show refractory skin disease to even systemic use of GCs and MTX. Hydroxychloroquine (HCQ) has been reported to improve skin manifestations associated with JDM and is used globally for JDM. However, HCQ is not approved by the Ministry of Health, Labour and Welfare of Japan for treatment of JDM. Herein, we report two patients with JDM presenting with residual skin disease after taking systemic GC and immunosuppressants, which was successfully treated with HCQ. HCQ was effective for treating a case with skin symptoms without significant muscle weakness at relapse and for a case with residual skin symptoms after showing improvement of muscle symptoms with systemic GCs and immunosuppressants. No adverse events were observed in their clinical courses. Thus, HCQ may be an effective choice as an adjunctive therapy for refractory skin symptom-dominant JDM.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf037","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:10:41Z","timestamp":1751875841000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of hydroxychloroquine treatment for the skin manifestations of juvenile dermatomyositis"],"prefix":"10.1093","volume":"9","author":[{"given":"Asami","family":"Shimbo","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuya","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Irabu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Akutsu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Mouri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]},{"name":"Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine , Kawasaki ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Lifelong Immunotherapy, Institute of Science Tokyo , Tokyo ,","place":["Japan"]},{"name":"Department of Pediatrics and Adolescent Medicine, Juntendo University Nerima Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Lifelong Immunotherapy, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-7772","authenticated-orcid":false,"given":"Masaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2025080410014488500_ref1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14397595.2020.1718866","article-title":"Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-update","volume":"30","author":"Kobayashi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025080410014488500_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","article-title":"Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists","volume":"29","author":"Kohsaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2025080410014488500_ref3","first-page":"1545","article-title":"Adjunctive use of hydroxychloroquine in childhood dermatomyositis","volume":"16","author":"Olson","year":"1989","journal-title":"J Rheumatol"},{"key":"2025080410014488500_ref4","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3899\/jrheum.090953","article-title":"Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey","volume":"37","author":"Stringer","year":"2010","journal-title":"J Rheumatol"},{"key":"2025080410014488500_ref5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025080410014488500_ref6","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"2025080410014488500_ref7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol"},{"key":"2025080410014488500_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025080410014488500_ref9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ophtha.2015.01.014","article-title":"Pericentral hydroxychloroquine retinopathy in Korean patients","volume":"122","author":"Lee","year":"2015","journal-title":"Ophthalmology"},{"key":"2025080410014488500_ref10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"2025080410014488500_ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025080410014488500_ref12","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"2025080410014488500_ref13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/acr2.11605","article-title":"Higher odds of adverse cutaneous reactions in patients with dermatomyositis treated with hydroxychloroquine compared with methotrexate","volume":"5","author":"Allenzara","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025080410014488500_ref14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol"},{"key":"2025080410014488500_ref15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamadermatol.2018.2549","article-title":"Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf037\/63687043\/rxaf037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf037\/63687043\/rxaf037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf037\/63687043\/rxaf037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T14:01:50Z","timestamp":1754316110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf037\/8190041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf037","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf037"}}